- September 17, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Infectious Disease » Fungal Infections » Candidiasis
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Infectious Disease » Fungal Infections » Candidiasis
Background
Candidiasis is most commonly seen as a secondary infection in immunocompromised patients. Thrush is the common name for candidiasis of the mouth. It appears as white patches on the throat, tongue, and other mouth areas.
Other symptoms of thrush include soreness and difficulty swallowing. They only become pathogenic when favorable conditions exist. It can affect the vagina, mouth, penis, and other body areas.
Epidemiology
Candidiasis is prevalent in infancy and old age. Thrush affects approximately 37% of newborns in the United States. Oral candidiasis is common in children with a history of inhaled steroids. It is common in women during pregnancy. Thrush could be the first sign of HIV infection.
Thrush is widespread and more common in undernourished populations and affects both men and women equally. Even though Candida albicans is the predominant cause of candidiasis, non-Candida species have risen in recent years.
It is critical to understand non-albicans species because treatment varies according to species. Fluconazole resistance may exist in Candida species other than Albicans. Invasive and disseminative candidiasis is becoming more common worldwide, and individuals with compromised immune systems are particularly vulnerable.
Anatomy
Pathophysiology
Candida enters the bloodstream via three routes: the most common is through the gastrointestinal tract mucosal barrier, followed by an intravascular catheter and a localized infection. Candida can enter the bloodstream of both neutropenic and intensive care unit patients. They are also a normal part of the gut microflora, and a person immunocompromised status can lead to bloodstream candidiasis.
Candida growth in indwelling catheters, particularly central lines, can occur at either the implantation site or the hub, leading to the subsequent Candida infection. Candida albicans typically colonize thrush in neonates during the passage via the infected vagina, with an active vaginal yeast infection, the neonate’s chances of developing thrush increase.
The use of local or systemic antimicrobial therapy may precipitate vulvovaginal candidiasis, and it may also polymerize frequent episodes of disease. Bloodstream invasion from a localized infection is uncommon, but it is common with ascending Candida urinary tract infections associated with either innate obstruction or external compression.
Etiology
Candida albicans cause mucosal candidiasis when present in an immunocompromised host. Patients with leukemia or lymphoma who have been administered corticosteroids or cytotoxic drugs have deteriorated immunity, which leads to candidal infection. Antibiotic use is frequently linked to candidiasis.
Cancer cytotoxic chemotherapy can cause Candida albicans fungemia, which develops from fungal translocation via vulnerable mucosal barriers. Due to changes in intrinsic bacterial composition or population and the host environment, fungi in the upper and lower GI tract can develop opportunistic pathogens.
Pregnancy, diabetes mellitus, and oral contraceptives increase vaginal colonization. Oral candidiasis is strongly linked to HIV patients. Candida infection affects more than 90% of HIV patients.
Myxedema, tuberculosis, hypoparathyroidism, nutritional deficiency, Addison’s disease, smoking, IV tubes, poorly maintained dentures, catheters, heart valves, infancy, pregnancy, and old age are all risk factors for candidiasis. Because of the lack of protective antifungal proteins, histatin, and calprotectin, xerostomia is also a risk factor.
Genetics
Prognostic Factors
Untreated Candida infections can spread to other organs and cause a systemic infection. The long-term prognosis of systemic candidiasis is determined by the severity and site of the Candida infection, the infected person’s overall health, and the timeframe of diagnosis and treatment.
Almost one-third of candidemia patients develop septic shock due to host factors such as age and source of infection rather than intrinsic virulence variables of organisms.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Oesophageal candidiasis
200mg orally on day 1, then 100mg every day
Oropharyngeal candidiasis
200mg orally on day 1, then 100mg every day
Prophylaxis of candidiasis with bone marrow transplantation
400mg orally every day
Indicated for candida UTI/peritonitis:
50-200mg orally every day
5g of the cream (1 applicatorful of cream) administered intravaginally as a single dose
Extend the dose for 6 days only in the second and third trimesters of pregnancy (Not recommended in the first trimester)
Esophageal Candidiasis
150mg/day intravenous administration for 10 to 30 days
Candida Infections in HSCT Recipients Prophylaxis
50mg/day intravenous administration for 6 to 51 days
Treatment of acute disseminated candidiasis, candidemia, abscesses, and candida peritonitis
100mg/day intravenous administration for 10 to 47 days
50-150 mg/kg orally each day divided every 6 hours
Take the dose with a plenty glass full of water
In the case of renal impairment, adjust the dose
If more than one capsule is taken, keep a gap of 15 minutes between each swallow to prevent vomiting and nausea
Oropharyngeal candidiasis
6mg/kg orally on day 1, then 3mg/kg daily
Do not exceed 600mg/day
Oesophageal candidiasis
6mg/kg orally on day 1, then 3mg/kg daily
Do not exceed 600mg/day
Systemic candida infections
6-12mg/kg/day orally or intravenously. Do not exceed 600mg/day
Four months and older
Esophageal Candidiasis
>30 kgs: 2.5 mg/kg intravenous every day. Do not exceed 150mg/day
≤30 kgs: 3 mg/kg intravenous every day
Candida Infections in HSCT Recipients Prophylaxis
1 mg/kg intravenous every day. Do not exceed 50mg/day
Treatment of acute disseminated candidiasis, candidemia, abscesses, and candida peritonitis
2 mg/kg intravenous every day. Do not exceed 100mg/day
younger than four months old
4mg/kg intravenous everyday
For children- 50-150 mg/kg orally each day divided every 6 hours
For neonates (less than 28 years old)- 80-160 mg/kg orally each day divided every 6 hours
In the case of renal impairment, adjust the dose
Future Trends
References
https://www.ncbi.nlm.nih.gov/books/NBK560624/
ADVERTISEMENT
» Home » CAD » Infectious Disease » Fungal Infections » Candidiasis
Candidiasis is most commonly seen as a secondary infection in immunocompromised patients. Thrush is the common name for candidiasis of the mouth. It appears as white patches on the throat, tongue, and other mouth areas.
Other symptoms of thrush include soreness and difficulty swallowing. They only become pathogenic when favorable conditions exist. It can affect the vagina, mouth, penis, and other body areas.
Candidiasis is prevalent in infancy and old age. Thrush affects approximately 37% of newborns in the United States. Oral candidiasis is common in children with a history of inhaled steroids. It is common in women during pregnancy. Thrush could be the first sign of HIV infection.
Thrush is widespread and more common in undernourished populations and affects both men and women equally. Even though Candida albicans is the predominant cause of candidiasis, non-Candida species have risen in recent years.
It is critical to understand non-albicans species because treatment varies according to species. Fluconazole resistance may exist in Candida species other than Albicans. Invasive and disseminative candidiasis is becoming more common worldwide, and individuals with compromised immune systems are particularly vulnerable.
Candida enters the bloodstream via three routes: the most common is through the gastrointestinal tract mucosal barrier, followed by an intravascular catheter and a localized infection. Candida can enter the bloodstream of both neutropenic and intensive care unit patients. They are also a normal part of the gut microflora, and a person immunocompromised status can lead to bloodstream candidiasis.
Candida growth in indwelling catheters, particularly central lines, can occur at either the implantation site or the hub, leading to the subsequent Candida infection. Candida albicans typically colonize thrush in neonates during the passage via the infected vagina, with an active vaginal yeast infection, the neonate’s chances of developing thrush increase.
The use of local or systemic antimicrobial therapy may precipitate vulvovaginal candidiasis, and it may also polymerize frequent episodes of disease. Bloodstream invasion from a localized infection is uncommon, but it is common with ascending Candida urinary tract infections associated with either innate obstruction or external compression.
Candida albicans cause mucosal candidiasis when present in an immunocompromised host. Patients with leukemia or lymphoma who have been administered corticosteroids or cytotoxic drugs have deteriorated immunity, which leads to candidal infection. Antibiotic use is frequently linked to candidiasis.
Cancer cytotoxic chemotherapy can cause Candida albicans fungemia, which develops from fungal translocation via vulnerable mucosal barriers. Due to changes in intrinsic bacterial composition or population and the host environment, fungi in the upper and lower GI tract can develop opportunistic pathogens.
Pregnancy, diabetes mellitus, and oral contraceptives increase vaginal colonization. Oral candidiasis is strongly linked to HIV patients. Candida infection affects more than 90% of HIV patients.
Myxedema, tuberculosis, hypoparathyroidism, nutritional deficiency, Addison’s disease, smoking, IV tubes, poorly maintained dentures, catheters, heart valves, infancy, pregnancy, and old age are all risk factors for candidiasis. Because of the lack of protective antifungal proteins, histatin, and calprotectin, xerostomia is also a risk factor.
Untreated Candida infections can spread to other organs and cause a systemic infection. The long-term prognosis of systemic candidiasis is determined by the severity and site of the Candida infection, the infected person’s overall health, and the timeframe of diagnosis and treatment.
Almost one-third of candidemia patients develop septic shock due to host factors such as age and source of infection rather than intrinsic virulence variables of organisms.
Oesophageal candidiasis
200mg orally on day 1, then 100mg every day
Oropharyngeal candidiasis
200mg orally on day 1, then 100mg every day
Prophylaxis of candidiasis with bone marrow transplantation
400mg orally every day
Indicated for candida UTI/peritonitis:
50-200mg orally every day
5g of the cream (1 applicatorful of cream) administered intravaginally as a single dose
Extend the dose for 6 days only in the second and third trimesters of pregnancy (Not recommended in the first trimester)
Esophageal Candidiasis
150mg/day intravenous administration for 10 to 30 days
Candida Infections in HSCT Recipients Prophylaxis
50mg/day intravenous administration for 6 to 51 days
Treatment of acute disseminated candidiasis, candidemia, abscesses, and candida peritonitis
100mg/day intravenous administration for 10 to 47 days
50-150 mg/kg orally each day divided every 6 hours
Take the dose with a plenty glass full of water
In the case of renal impairment, adjust the dose
If more than one capsule is taken, keep a gap of 15 minutes between each swallow to prevent vomiting and nausea
Oropharyngeal candidiasis
6mg/kg orally on day 1, then 3mg/kg daily
Do not exceed 600mg/day
Oesophageal candidiasis
6mg/kg orally on day 1, then 3mg/kg daily
Do not exceed 600mg/day
Systemic candida infections
6-12mg/kg/day orally or intravenously. Do not exceed 600mg/day
Four months and older
Esophageal Candidiasis
>30 kgs: 2.5 mg/kg intravenous every day. Do not exceed 150mg/day
≤30 kgs: 3 mg/kg intravenous every day
Candida Infections in HSCT Recipients Prophylaxis
1 mg/kg intravenous every day. Do not exceed 50mg/day
Treatment of acute disseminated candidiasis, candidemia, abscesses, and candida peritonitis
2 mg/kg intravenous every day. Do not exceed 100mg/day
younger than four months old
4mg/kg intravenous everyday
For children- 50-150 mg/kg orally each day divided every 6 hours
For neonates (less than 28 years old)- 80-160 mg/kg orally each day divided every 6 hours
In the case of renal impairment, adjust the dose
https://www.ncbi.nlm.nih.gov/books/NBK560624/
Candidiasis is most commonly seen as a secondary infection in immunocompromised patients. Thrush is the common name for candidiasis of the mouth. It appears as white patches on the throat, tongue, and other mouth areas.
Other symptoms of thrush include soreness and difficulty swallowing. They only become pathogenic when favorable conditions exist. It can affect the vagina, mouth, penis, and other body areas.
Candidiasis is prevalent in infancy and old age. Thrush affects approximately 37% of newborns in the United States. Oral candidiasis is common in children with a history of inhaled steroids. It is common in women during pregnancy. Thrush could be the first sign of HIV infection.
Thrush is widespread and more common in undernourished populations and affects both men and women equally. Even though Candida albicans is the predominant cause of candidiasis, non-Candida species have risen in recent years.
It is critical to understand non-albicans species because treatment varies according to species. Fluconazole resistance may exist in Candida species other than Albicans. Invasive and disseminative candidiasis is becoming more common worldwide, and individuals with compromised immune systems are particularly vulnerable.
Candida enters the bloodstream via three routes: the most common is through the gastrointestinal tract mucosal barrier, followed by an intravascular catheter and a localized infection. Candida can enter the bloodstream of both neutropenic and intensive care unit patients. They are also a normal part of the gut microflora, and a person immunocompromised status can lead to bloodstream candidiasis.
Candida growth in indwelling catheters, particularly central lines, can occur at either the implantation site or the hub, leading to the subsequent Candida infection. Candida albicans typically colonize thrush in neonates during the passage via the infected vagina, with an active vaginal yeast infection, the neonate’s chances of developing thrush increase.
The use of local or systemic antimicrobial therapy may precipitate vulvovaginal candidiasis, and it may also polymerize frequent episodes of disease. Bloodstream invasion from a localized infection is uncommon, but it is common with ascending Candida urinary tract infections associated with either innate obstruction or external compression.
Candida albicans cause mucosal candidiasis when present in an immunocompromised host. Patients with leukemia or lymphoma who have been administered corticosteroids or cytotoxic drugs have deteriorated immunity, which leads to candidal infection. Antibiotic use is frequently linked to candidiasis.
Cancer cytotoxic chemotherapy can cause Candida albicans fungemia, which develops from fungal translocation via vulnerable mucosal barriers. Due to changes in intrinsic bacterial composition or population and the host environment, fungi in the upper and lower GI tract can develop opportunistic pathogens.
Pregnancy, diabetes mellitus, and oral contraceptives increase vaginal colonization. Oral candidiasis is strongly linked to HIV patients. Candida infection affects more than 90% of HIV patients.
Myxedema, tuberculosis, hypoparathyroidism, nutritional deficiency, Addison’s disease, smoking, IV tubes, poorly maintained dentures, catheters, heart valves, infancy, pregnancy, and old age are all risk factors for candidiasis. Because of the lack of protective antifungal proteins, histatin, and calprotectin, xerostomia is also a risk factor.
Untreated Candida infections can spread to other organs and cause a systemic infection. The long-term prognosis of systemic candidiasis is determined by the severity and site of the Candida infection, the infected person’s overall health, and the timeframe of diagnosis and treatment.
Almost one-third of candidemia patients develop septic shock due to host factors such as age and source of infection rather than intrinsic virulence variables of organisms.
https://www.ncbi.nlm.nih.gov/books/NBK560624/
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.